



Date: November 22, 2021
To: All Island Health Staff and Physicians
From: Richard Jones, Director, Pharmacy Services
Infection Management Advisory Committee (IMAC)

RE: casirivimab + imdevimab (REGEN-COV) injection for COVID-19: Use and Access

Situation:

The BC COVID-19 Therapeutics Committee (CTC) revised their clinical practice guidance regarding casirivimab + imdevimab (REGEN-COV) injection for the treatment of inpatients with COVID-19. As drug supply is limited, REGEN-COV is recommended for patients who are hospitalized with confirmed SARS-CoV-2 infection who are severely ill from symptoms of COVID-19, plus criteria as outlined in the [Clinical Practice Guide for the Use of REGEN-COV in Inpatients with COVID-19](#).

Background:

Casirivimab + imdevimab is a combination of two non-competing, recombinant human IgG1 monoclonal antibodies. Each antibody targets the spike protein of SARS-CoV-2. The blockage of the interaction with angiotensin-converting enzyme 2 (ACE2) leads to inhibition of infection of host cells. Casirivimab + imdevimab may also be known by the brand names REGENERON or RONAPREVE. **Casirivimab + imdevimab is non-Formulary for BC hospitals.**

Guidance:

Casirivimab 1.2 g + imdevimab 1.2 g (REGEN-COV) IV x 1 dose is recommended for patients:

- Hospitalized with confirmed SARS-CoV-2 infection & severely, but not critically, ill, AND
- Within 10 days of symptom onset, AND
- Seronegative for COVID-19 anti-spike antibody (irrespective of COVID-19 vaccine status). casirivimab + imdevimab can be given without serostatus results if the patient is deteriorating significantly AND is likely seronegative due to being unimmunized, partially immunized, or having had previous inadequate response to vaccination.

*Please see [Clinical Practice Guide for the Use of REGEN-COV in Inpatients with COVID-19](#) created by the BC COVID Therapeutics Committee (BC CTC).

Drug supply is limited and will be supplied on a first come, first serve basis. Island Health sites should share supply to address new orders as required for equitable distribution.

Use of casirivimab + imdevimab is restricted to prescribing or approval by Intensivists or Infectious Disease physicians.

To contact an Infectious Disease physician to review casirivimab + imdevimab, refer to the on-call schedule system: <https://medicalaffairs.viha.ca/oncall/BrowseSchedules/>. Under Infectious Diseases, select ID physician on call for either NRGH, RJH, or VGH Infectious Diseases. If there is no doctor listed for NRGH, please call the RJH contact covering.

[casirivimab + imdevimab IV Info Sheet](#)

Online COVID Resources:

[COVID-19 Main Page](#)

[Medication Related Guidance and Recommendations](#)